CML was the first cancer to benefit from a targeted therapy in the early 2000s with STI571/Imatinib, a tyrosine kinase inhibitor (TKI), that specifically blocks ABL activity. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.